Want to see TPST full AI Analyst Report?
Top Page
Tempest Therapeutics
(NASDAQ:TPST)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.00
▲(8.70% Upside)
Action:Reiterated
Date:08/19/26
The score is held down primarily by very weak financial performance (no revenue, large losses, cash burn, and negative equity), which raises ongoing funding and dilution risk. Technicals show only modest near-term stabilization while the longer-term trend remains down. Corporate events are mixed—improved access to capital and partnership progress are tempered by Nasdaq listing/governance concerns and continued dilution-related actions—while valuation offers limited support due to negative earnings and no dividend.
Positive Factors
Flexible funding access
The equity facility gives Tempest discretion to draw capital over time rather than raise the full amount at once. This improves financing flexibility for clinical development, although access remains dependent on market and regulatory conditions.
Negative Factors
Pre-revenue operating model
Tempest has no commercial revenue base to offset research and development costs, leaving value dependent on clinical progress, partnering, or eventual product launches. Persistent losses make profitability highly uncertain over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Flexible funding access
The equity facility gives Tempest discretion to draw capital over time rather than raise the full amount at once. This improves financing flexibility for clinical development, although access remains dependent on market and regulatory conditions.
Read all positive factors
Tempest Therapeutics (TPST) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.62M
Dividend YieldN/A
Average Volume (3M)50.79K
Price to Earnings (P/E)―
Beta (1Y)1.74
Revenue GrowthN/A
EPS Growth69.34%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.48
Shares Outstanding15,979,411
10 Day Avg. Volume57,939
30 Day Avg. Volume50,791
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.44
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.34
Revenue Forecast (FY)N/A
Tempest Therapeutics Business Overview & Revenue Model
Company Description
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a...
How the Company Makes Money
Tempest Therapeutics is a clinical-stage biotech and does not primarily operate a mature product-sales business. Its cash generation typically comes from (a) collaboration and licensing arrangements (e.g., upfront payments, research funding or cos...
Tempest Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -22.18M | 0.00 | -389.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -40.29M | -25.79M | -40.14M | -27.66M | -33.45M | -26.65M |
| Net Income | -40.47M | -26.26M | -41.84M | -29.49M | -35.71M | -28.30M |
Balance Sheet | ||||||
| Total Assets | 9.63M | 16.93M | 41.49M | 51.60M | 46.09M | 73.24M |
| Cash, Cash Equivalents and Short-Term Investments | 779.00K | 7.71M | 30.27M | 39.23M | 31.23M | 51.83M |
| Total Debt | 7.56M | 8.14M | 15.37M | 20.66M | 22.11M | 18.54M |
| Total Liabilities | 10.72M | 10.26M | 22.36M | 24.84M | 27.98M | 37.12M |
| Stockholders Equity | -1.09M | 6.67M | 19.13M | 26.77M | 18.11M | 36.12M |
Cash Flow | ||||||
| Free Cash Flow | -20.73M | -26.82M | -33.46M | -27.53M | -31.63M | -26.09M |
| Operating Cash Flow | -20.73M | -26.82M | -33.03M | -27.36M | -31.07M | -25.96M |
| Investing Cash Flow | 0.00 | 0.00 | -435.00K | -170.00K | -562.00K | -97.00K |
| Financing Cash Flow | 7.23M | 4.26M | 24.50M | 35.60M | 11.40M | 59.06M |
Tempest Therapeutics Technical Analysis
Negative
0.92
Price Trends
1.05
Negative
1.41
Negative
2.41
Negative
Market Momentum
0.01
Negative
50.19
Neutral
29.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TPST, the sentiment is Negative. The current price of 0.92 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.05, and below the 200-day MA of 2.41, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 50.19 is Neutral, neither overbought nor oversold. The STOCH value of 29.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TPST.
Tempest Therapeutics Risk Analysis
Tempest Therapeutics disclosed 79 risk factors in its most recent earnings report. Tempest Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tempest Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $34.59M | 3.06 | 83.42% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $29.91M | -1.44 | -456.35% | ― | ― | 9.68% | |
45 Neutral | $12.23M | -0.34 | -346.03% | ― | ― | 30.16% | |
44 Neutral | $19.56M | -0.42 | 4092.98% | ― | ― | 15.37% | |
43 Neutral | $16.62M | -0.23 | -729.89% | ― | ― | 69.34% |
* Healthcare Sector Average
TPST
Tempest Therapeutics
1.04
-9.53
-90.16%
ATNM
Actinium Pharmaceuticals
1.10
-0.69
-38.55%
PDSB
PDS Biotechnology
0.22
-1.08
-83.23%
LTRN
Lantern Pharma
2.34
-2.23
-48.80%
CALC
CalciMedica
0.57
-2.22
-79.50%
Tempest Therapeutics Corporate Events
Business Operations and StrategyShareholder Meetings
Tempest Therapeutics Adjourns Special Stockholder Meeting Again
Negative
Aug 18, 2026
On August 17, 2026, Tempest Therapeutics reconvened a special meeting of stockholders originally convened and adjourned on July 27, 2026, to seek approval of an amendment to its Restated Certificate of Incorporation that would replace certain supe...
Business Operations and StrategyPrivate Placements and Financing
Tempest Therapeutics Secures Flexible $50 Million Equity Facility
Positive
Aug 13, 2026
On August 13, 2026, Tempest Therapeutics entered into a purchase and registration rights agreement with Lincoln Park Capital Fund, under which Lincoln Park committed to buy up to $50 million of Tempest’s common stock over 24 months, starting...
Business Operations and StrategyShareholder Meetings
Tempest Therapeutics Adjourns Vote on Governance Changes
Neutral
Jul 28, 2026
On July 27, 2026, Tempest Therapeutics convened a special meeting of stockholders to seek approval of an amendment to its Restated Certificate of Incorporation that would eliminate certain supermajority voting requirements and allow stockholder ac...
Business Operations and StrategyProduct-Related Announcements
Tempest Therapeutics inks China in vivo CAR-T deal
Positive
Jul 22, 2026
On July 17, 2026, Tempest Therapeutics entered a collaboration agreement with Hebei Senlang Biotechnology to co-develop Tempest’s in vivo CAR-T product candidates in China, starting with TPST-4003. The deal positions Tempest to leverage Senl...
Private Placements and FinancingShareholder Meetings
Tempest Stockholders Approve Warrant-Related Share Issuances
Positive
Jun 23, 2026
On June 18, 2026, Tempest Therapeutics held a special meeting of stockholders at which investors approved the issuance of up to 925,927 shares of common stock upon exercise of outstanding Series A warrants and an additional 925,927 shares upon exe...
Executive/Board ChangesDelistings and Listing ChangesRegulatory Filings and Compliance
Tempest Therapeutics Announces CFO Transition and Board Changes
Neutral
Jun 4, 2026
On May 29, 2026, Tempest Therapeutics disclosed that Chief Financial Officer Nicholas Maestas had resigned effective June 5, 2026, and on that date the board appointed longtime finance executive Justin Trojanowski as Vice President, Finance, Princ...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Tempest Therapeutics Executes Warrant-Inducement Equity Financing Deal
Neutral
Jun 2, 2026
On May 28, 2026, Tempest Therapeutics entered into an inducement agreement with a holder of warrants originally issued in November 2025, cutting the exercise price from $3.50 to $1.73 per share in exchange for the holder exercising warrants for 1,...
Executive/Board Changes
Tempest Therapeutics Announces Resignation of Board Director
Neutral
May 29, 2026
On May 23, 2026, Tempest Therapeutics, Inc. announced that Ms. Simantov resigned from its Board of Directors, with the company stating it had not been informed of any disagreement related to its operations, policies, or practices underlying her de...
Executive/Board ChangesDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Tempest Therapeutics Faces Nasdaq Listing and Governance Risks
Negative
May 22, 2026
On May 19, 2026, Tempest Therapeutics received a deficiency notice from Nasdaq after reporting stockholders’ equity of $822,000 as of March 31, 2026, far below the $2.5 million minimum required for continued listing on the Nasdaq Capital Mar...
Executive/Board Changes
Tempest Therapeutics Announces Multiple Board Director Resignations
Neutral
May 22, 2026
On May 22, 2026, Tempest Therapeutics, Inc. announced that directors Stephen Brady, Michael Raab and Christine Pellizzari resigned from its board of directors, with the company stating it had not been informed of any disagreements related to opera...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.